RxDoctor Payments Data

Stephanie Sarrat, MD

Internal Medicine · New Orleans, LANPI 1376543876

Payments from drug & device makers

$4,270in general payments, 2019–2025

Across 279 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$695
  • Lilly USA, LLC$626
  • Pfizer$498
  • Novo Nordisk$379
  • Bayer$263
  • AstraZeneca$245
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,270 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$39,325
Medicare patients
143
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$102,896
EliquisApixaban81$73,287
TrulicityDulaglutide51$71,384
OzempicSemaglutide41$67,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$45,420
MounjaroTirzepatide27$35,360
JanuviaSitagliptin Phosphate26$29,326
Soliqua 100-33Insulin Glargine/Lixisenatide28$28,923
XareltoRivaroxaban22$24,512
Combivent RespimatIpratropium/Albuterol Sulfate13$10,365
MyrbetriqMirabegron12$8,756
TradjentaLinagliptin17$8,691
VeozahFezolinetant12$6,493
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,299
Incruse ElliptaUmeclidinium Bromide12$5,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$126$121,953127 claims
Lilly USA, LLCTrulicity, Mounjaro$626$106,74478 claims
PfizerEliquis$498$73,28781 claims
Novo NordiskOzempic$379$67,82841 claims
GSKTrelegy Ellipta, Incruse Ellipta$695$50,49846 claims
MerckJanuvia$25$29,32626 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$145$28,92328 claims
Johnson & JohnsonXarelto$45$24,51222 claims
Astellas Pharma US IncMyrbetriq, Veozah$160$15,24924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →